WO2023119239 - METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE
National phase entry is expected:
Publication Number
WO/2023/119239
Publication Date
29.06.2023
International Application No.
PCT/IB2022/062711
International Filing Date
23.12.2022
Title **
[English]
METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE
[French]
MÉTHODE DE TRAITEMENT DE LA MALADIE DU GREFFON CONTRE L'HÔTE AIGUË
Applicants **
MESOBLAST INTERNATIONAL SARL
Inventors
ITESCU, Silviu
Priority Data
2021904222
23.12.2021
AU
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3204 | |
| EPO | Filing, Examination, Granting | 26640 | |
| Japan | Filing, Examination, Granting | 3236 | |
| South Korea | Filing, Examination, Granting | 4272 | |
| USA | Filing, Examination, Granting | 10740 |
Total:
48,092
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to mesenchymal lineage precursor or stem cell mediated methods for treating severe Graft versus Host Disease (GvHD) in subjects at high risk of poor outcomes.[French]
La présente invention concerne des méthodes médiées par des précurseurs de lignées mésenchymateuses ou des cellules souches pour le traitement de la maladie du greffon contre l'hôte (GvHD) aiguë chez des sujets présentant un haut risque de mauvais résultats.